Related Experiment Video
Updated: Feb 27, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
DUSP1: Triple-Negative Breast Cancer and Therapeutic Potential
Suryakant Niture1,2, Dinesh Thotala1,2, Jerry Jaboin1,2
1Department of Radiation Oncology, Oklahoma University Health Sciences Center, Oklahoma City, OK 73104, USA.
Abstract:
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by high rates of recurrence, limited targeted treatment options, and frequent resistance to standard therapies. Dual-specificity protein phosphatase 1 (DUSP1), a stress-responsive regulator of mitogen-activated protein kinase (MAPK) signaling, has emerged as a context-dependent modulator of tumor progression and therapeutic response in TNBC. While reduced DUSP1 expression has been associated with aggressive tumor phenotypes and poor prognosis, accumulating evidence indicates that therapy-induced upregulation of DUSP1 can promote resistance to chemotherapy and radiotherapy by attenuating pro-apoptotic MAPK signaling and fostering immunosuppressive tumor microenvironment (TME). Emerging evidence highlights that DUSP1's role is context-dependent on human cancers, including breast cancer (BC). This review synthesizes current evidence on DUSP1 biology in TNBC, with emphasis on its mechanistic involvement in chemotherapy resistance, radiation-induced immune modulation, and emerging implications for immunotherapy response.
Insights
Dual-specificity protein phosphatase 1 (DUSP1) plays a complex role in triple-negative breast cancer (TNBC). While low DUSP1 may indicate aggressive tumors, its therapy-induced increase can drive treatment resistance and immune evasion in TNBC.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its aggressive nature, recurrence rates, and resistance to conventional treatments.
- Dual-specificity protein phosphatase 1 (DUSP1), a key regulator of mitogen-activated protein kinase (MAPK) signaling, exhibits context-dependent functions in cancer progression and treatment response.
- While decreased DUSP1 expression correlates with poor prognosis in TNBC, its upregulation during therapy can paradoxically promote resistance.
Purpose of the Study:
- To review and synthesize current evidence on the multifaceted role of DUSP1 in TNBC.
- To elucidate DUSP1's mechanisms in chemotherapy and radiotherapy resistance.
- To explore DUSP1's impact on the tumor microenvironment and its implications for immunotherapy.
Main Methods:
- Literature review and synthesis of existing research on DUSP1 in TNBC.
- Analysis of DUSP1's involvement in MAPK signaling pathways.
- Examination of DUSP1's role in modulating the tumor microenvironment (TME) and immune responses.
Main Results:
- Reduced DUSP1 expression is linked to aggressive TNBC phenotypes and poorer patient outcomes.
- Therapy-induced upregulation of DUSP1 can confer resistance to chemotherapy and radiotherapy by inhibiting pro-apoptotic signaling.
- DUSP1 influences the TME, potentially fostering an immunosuppressive environment that impacts treatment efficacy.
Conclusions:
- DUSP1's role in TNBC is highly context-dependent, acting as both a potential tumor suppressor and a mediator of therapeutic resistance.
- Understanding DUSP1's dual function is crucial for developing novel therapeutic strategies targeting TNBC.
- Further research into DUSP1 modulation may offer new avenues for overcoming treatment resistance and enhancing immunotherapy outcomes in TNBC.
